Tarsus Pharmaceuticals, Inc. TARS Total Operating Expenses
Discontinued — last reported Q4 '23
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 27, 2024, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s total operating expenses?
- Tarsus Pharmaceuticals, Inc. (TARS) reported total operating expenses of $40.15M in Q4 2023.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.